[Phase II clinical study of a new anticancer drug boanmycin].
To evaluate the efficacy of boanmycin (BAM) in patients with advanced cancers. A multicenter phase II clinical study on BAM was conducted on 105 cases received BAM as single agent, and 220 cases were treated with combination chemotherapy containing BAM. The total response rate was 35.0% for single agent and 64.2% for combination chemotherapy group in advanced cancers. The response rate for single agent in malignant lymphoma, cancer of head and neck and breast cancer was 66.7%, 65.0% and 37.5%, respectively; and for combination chemotherapy group in malignant lymphoma, breast cancer, head and neck cancer, esophageal cancer and lung cancer was 88.5%, 62.5%, 50.0%, 47.2% and 45.8%, respectively. The main side effects with mild or moderate fever, chill, myalgia, gastrointestinal reactions, skin pigmentation as well as hardening of skin at injection site. BAM therapy was effective in malignant lymphoma, cancer of head and neck and other cancers.